Jun 29 2005
BASF will acquire 100 percent of the Swiss fine chemicals company Orgamol S.A. The necessary majority of Orgamol’s Swiss employees today (June 25, 2005) approved with more than 99 percent the sale of their 25 percent combined shareholding to BASF at a meeting held in Evionnaz, Switzerland. At the beginning of June 2005, BASF had already reached an agreement with the private owners regarding the sale of their 75 percent share in Orgamol. The transaction is still subject to approval by the competent authorities.
“We are pleased that Orgamol’s employees have voted in favor of this transaction. Their expertise will play a great part in ensuring our long-term success in the face of international competition,” said Martin Laudenbach, head of BASF’s Fine Chemicals division. The acquisition of Orgamol will place BASF among the top 10 providers of pharma contract manufacturing solutions in the world.
The global contract manufacturing business will be managed from Switzerland. As a result, a small number of employees from BASF’s Pharma Solutions unit will be relocated from Limburgerhof, Germany, to Orgamol’s headquarters in Evionnaz.
BASF offers an extensive range of pharmaceutical active ingredients and excipients. Following this transaction, approximately 1,250 employees worldwide will work for the Pharma Solutions business, which is part of BASF’s Fine Chemicals operating division. This division globally develops, produces and markets high-value products for human and animal nutrition and for the cosmetics and pharmaceutical industries.
http://www.basf.com